DEA Moves to Place High-Concentration 7-Hydroxymitragynine in Schedule I, Putting Supplement Market on Opioid-Risk Red Line

The U.S. Drug Enforcement Administration (DEA) is preparing to take action against high-strength 7-hydroxymitragynine (7-OH) products. This is not only a regulatory escalation for the kratom market, but also reflects a shortening of regulators’ patience with the gray area between “plant-derived” and “opioid-like effects.” When an ingredient moves from trace presence in leaves to concentrated gummies, beverages, and capsules on convenience-store and smoke-shop shelves, the public health issue is no longer just traditional drug classification, but who is using it, how high the dose is, and how the risk is packaged.

According to a notice published in the Federal Register on July 6, the DEA proposes to temporarily place 7-OH above certain thresholds into Schedule I under the Controlled Substances Act. Schedule I control generally means authorities believe the substance has a high potential for abuse, currently has no accepted medical use in the United States, and lacks accepted safety for use under medical supervision. If completed, the temporary scheduling would target high-concentration 7-OH and related products, rather than treating all kratom plant material the same across the board.

The official document sets out the thresholds in considerable detail: kratom plant material would fall within the proposed control if its 7-OH content exceeds 0.050% by dry weight, or if products in non-plant material form exceed the corresponding weight or volume ratio, or if a single product contains more than 1.00 milligram. The DEA said the temporary scheduling order could be published as early as August 5, 2026, or thereafter; WIRED reported that the arrangement will go through a 30-day public comment period, with scheduling lasting two years and potentially being extended for another year.

7-OH has raised alarm because it is described as a kratom component with opioid-like effects. Traditional kratom leaves themselves have long been controversial over safety and dependence risks, but in recent years the market’s concerns have focused more on chemically processed or highly concentrated 7-OH products. These products often appear as over-the-counter, supplement, or recreational consumer goods, yet they may expose users to active substances at levels far above the background content in plant raw materials, blurring the line between foods, herbal products, and drugs.

The document also shows that the Department of Health and Human Services (HHS) informed the DEA on March 6, 2026, that the Food and Drug Administration (FDA) had not found an investigational new drug application (IND) or an approved new drug application (NDA) for the relevant substances, and that HHS had no objection to temporary placement in Schedule I. This reinforces the DEA’s regulatory argument: in the absence of approved medical use and standardized clinical evidence, the spread of concentrated products is viewed as closer to an uncontrolled drug market than to the general health-products market.

Industry and advocacy groups have not responded uniformly. WIRED reported that the American Kratom Association supports action against chemically manipulated 7-OH products, indicating that some kratom industry participants are also trying to separate traditional plant products from high-concentration derivatives. By contrast, 7-OH advocacy groups oppose the ban, possibly out of concern that scheduling would restrict users’ access and push the market toward more opaque channels. These differing positions are a reminder that the regulatory issue is not only “ban or do not ban,” but also how to define risky products versus ordinary plant materials.

If this temporary scheduling formally takes effect, the short-term impact will first fall on retailers, manufacturers, and enforcement practice: production, sale, and possession of products above the threshold could face tighter restrictions. The longer-term questions are more complex, including whether people with chronic pain and populations with substance use disorder will turn to other, higher-risk substitutes, whether existing product labeling is trustworthy, and, if 7-OH or kratom-related components are to be studied in the future, how sufficient materials and research authorization can be obtained under the control framework.

For biomedicine and public health, this case highlights an increasingly common regulatory challenge: active natural products do not need to become formal drugs before they can produce pharmacological strength and dependence risks. Once commercialized products simultaneously raise concentration, dosage form, and accessibility, traditional supplement regulation may fail to keep up. The DEA’s notice provides clear thresholds and a timeline, but public data still do not fully present the market size, user profile, or full picture of adverse events. That evidence will determine whether subsequent policy can strike a balance between reducing harm and avoiding unintended consequences.